Rezolute, Inc. (RZLT)Healthcare | Biotechnology | Redwood City, United States | NasdaqCM
3.90 USD
-0.33
(-7.801%) ⇩
(Oct. 15, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 2:52 a.m. EDT
The investment case for Rezolute is currently entirely binary and hinges on the outcome of its lead asset trials, specifically Ersodet. While the company recently gained ground following a positive FDA meeting, the historical price trajectory tells a stark story of volatility and decline, dropping nearly 88% over the last nine years despite occasional spikes. The balance sheet is fragile, with negative free cash flow and negative returns on equity, meaning the stock relies on capital markets or dilution to fund operations rather than organic cash generation. Short-term, the stock is trading near its 50-day moving average, showing some resilience after a recent 38% weekly jump, but the statistical forecast offers no directional edge. The options market confirms the speculative nature of the trade, with traders betting big on a potential 'moonshot' recovery if trials succeed, while hedging for a crash if they fail. There is no dividend to provide a floor. For investors, this is not a value play; it is a high-risk venture capital ticket where the thesis is either a massive biotech breakthrough or total erasure of value. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.102736 |
| AutoETS | 0.102741 |
| MSTL | 0.116212 |
| AutoTheta | 0.227632 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 33% |
| H-stat | 14.16 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.154 |
| Excess Kurtosis | -0.99 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.928 |
| Market Cap | 377,217,120 |
| Forward P/E | -8.37 |
| Beta | 0.54 |
| Website | https://www.rezolutebio.com |
As of Oct. 10, 2026, 2:52 a.m. EDT: Speculators are positioning for a binary event driven by clinical trial results. Call volume is heavily skewed toward out-of-the-money strikes (7.5 and 10.0) expiring in early 2027, suggesting a bet on a successful trial outcome that could drive the price significantly higher. Conversely, put volume concentrates at the 2.5 strike, indicating a hedge against trial failure or regulatory rejection. The heavy concentration of open interest at specific strikes implies these are key levels where market participants expect the price to resolve.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.55120826 |
| Address1 | 275 Shoreline Drive |
| Address2 | Suite 500 |
| All Time High | 750.0 |
| All Time Low | 0.72 |
| Ask | 5.93 |
| Ask Size | 2 |
| Audit Risk | 8 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 2,012,560 |
| Average Daily Volume3 Month | 1,494,781 |
| Average Volume | 1,494,781 |
| Average Volume10Days | 2,012,560 |
| Beta | 0.542 |
| Bid | 3.42 |
| Bid Size | 2 |
| Board Risk | 9 |
| Book Value | 1.044 |
| City | Redwood City |
| Compensation As Of Epoch Date | 1,798,675,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.9 |
| Current Ratio | 9.679 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 4.33 |
| Day Low | 3.9 |
| Debt To Equity | 0.928 |
| Display Name | Rezolute |
| Dividend Date | 1,602,547,200 |
| Dividend Yield | 0.0 |
| Earnings Timestamp | 1,790,280,000 |
| Earnings Timestamp End | 1,793,908,800 |
| Earnings Timestamp Start | 1,793,908,800 |
| Ebitda | -81,435,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -3.32 |
| Enterprise Value | 270,350,112 |
| Eps Current Year | -0.70889 |
| Eps Forward | -0.46571 |
| Eps Trailing Twelve Months | -0.75 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 4.4276 |
| Fifty Day Average Change | -0.5275998 |
| Fifty Day Average Change Percent | -0.11916158 |
| Fifty Two Week Change Percent | -55.120827 |
| Fifty Two Week High | 11.457 |
| Fifty Two Week High Change | -7.5569997 |
| Fifty Two Week High Change Percent | -0.65959674 |
| Fifty Two Week Low | 1.07 |
| Fifty Two Week Low Change | 2.83 |
| Fifty Two Week Low Change Percent | 2.6448596 |
| Fifty Two Week Range | 1.07 - 11.457 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,358,173,800,000 |
| Float Shares | 60,728,084 |
| Forward Eps | -0.46571 |
| Forward P E | -8.3743105 |
| Free Cashflow | -36,368,248 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 58 |
| Fullday Change | -0.24000001 |
| Fullday Change Percent | -5.673759 |
| Fullday Price | 3.9 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.097370006 |
| Held Percent Institutions | 0.98717004 |
| Implied Shares Outstanding | 96,722,333 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,782,777,600 |
| Last Split Date | 1,602,547,200 |
| Last Split Factor | 1:50 |
| Long Business Summary | Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California. |
| Long Name | Rezolute, Inc. |
| Market | us_market |
| Market Cap | 377,217,120 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_177932577 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -77,586,000 |
| Next Fiscal Year End | 1,814,313,600 |
| Non Diluted Market Cap | 385,169,324 |
| Number Of Analyst Opinions | 10 |
| Open | 4.25 |
| Operating Cashflow | -64,635,000 |
| Operating Margins | 0.0 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Phone | 650 206 4507 |
| Previous Close | 4.23 |
| Price Eps Current Year | -5.501559 |
| Price Hint | 4 |
| Price To Book | 3.7356322 |
| Profit Margins | 0.0 |
| Quick Ratio | 9.441 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.18182 |
| Region | US |
| Regular Market Change | -0.33 |
| Regular Market Change Percent | -7.80142 |
| Regular Market Day High | 4.33 |
| Regular Market Day Low | 3.9 |
| Regular Market Day Range | 3.9 - 4.33 |
| Regular Market Open | 4.25 |
| Regular Market Previous Close | 4.23 |
| Regular Market Price | 3.9 |
| Regular Market Time | 1,792,094,400 |
| Regular Market Volume | 2,117,116 |
| Return On Assets | -0.35317 |
| Return On Equity | -0.59043 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 7 |
| Shares Outstanding | 96,722,333 |
| Shares Percent Shares Out | 0.1728 |
| Shares Short | 16,714,969 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 16,998,710 |
| Short Name | Rezolute, Inc. |
| Short Percent Of Float | 0.22489999 |
| Short Ratio | 11.13 |
| Source Interval | 15 |
| State | CA |
| Symbol | RZLT |
| Target High Price | 15.0 |
| Target Low Price | 6.0 |
| Target Mean Price | 9.8 |
| Target Median Price | 10.0 |
| Total Cash | 107,801,000 |
| Total Cash Per Share | 1.115 |
| Total Debt | 934,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.75 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.80345 |
| Two Hundred Day Average Change | 0.09654999 |
| Two Hundred Day Average Change Percent | 0.025384843 |
| Type Disp | Equity |
| Volume | 2,117,116 |
| Website | https://www.rezolutebio.com |
| Zip | 94,065 |